Oncology

News

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

News

David Campbell, founder, president and CEO of Janux

Janux plans $200m offer on back of prostate cancer readout

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc

Oncology

Why is pharma going gaga for radiopharmaceuticals?

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.

News

Study rings warning bell over cancer therapy access in UK

Studies have suggested that cancer survival rates in the UK are lagging behind other countries by around 10 to 15 years because of lower rates of chemotherapy and radiothe

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

Pfizer’s new cancer unit sees eight new blockbusters by 2030

AbbVie inks $713m deal for OSE chronic inflammation drug

Janux plans $200m offer on back of prostate cancer readout

Why is pharma going gaga for radiopharmaceuticals?

Study rings warning bell over cancer therapy access in UK

Regeneron set for August FDA decision on BCMA bispecific

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks